Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
This multicentric analysis of tumours obtained from 140 patients with neuroblastoma confirms that the lack of CD44 expression is a highly significant factor of poor prognosis and, as previously published in multivariate analysis of the four factors, i.e. MYCN amplification, CD44 expression, age and tumour stage, CD44 expression and tumour stage were the only independent prognostic factors of event-free survival (Combaret et al., J Clin Oncol 1996, 14, 25-34). Furthermore, CD44 analysis affords significant prognostic discrimination in subgroups of patients with or without MYCN amplified tumours, both in low-stage neuroblastomas and high-grade neuroblastomas. In the subgroup of patients with low-stage neuroblastoma and the stage 4 subgroup, CD44 was the only independent prognostic factor for the prediction of event-free survival in a multivariate analysis. In conclusion, CD44 is one of the most powerful factors for predicting clinical outcome in neuroblastoma at the time of initial staging.
Combaret
V
V
Department of Tumour Biology, Centre Léon Bérard, Lyon, France.
Gross
N
N
Lasset
C
C
Frappaz
D
D
Beretta-Brognara
C
C
Philip
T
T
Beck
D
D
Favrot
M C
MC
D000367:Age Factors; D000951:Antigens, Neoplasm / Q000378:metabolism*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D005784:Gene Amplification; D016259:Genes, myc / Q000235:genetics*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D007223:Infant; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis
D000951:Antigens, Neoplasm; D018960:Hyaluronan Receptors